losudesivir   Click here for help

GtoPdb Ligand ID: 14618

Compound class: Synthetic organic
Comment: Losudesivir is the INN for an adenosine analogue that is intended as a coronavirus antiviral agent. The structure was obtained from WHO INN Proposed List 135 (July 2026). It represents an orally bioavailable RdRp inhibitor known by the codes SHEN26 and ATV014 that exhibits broad-spectrum activity against multiple coronaviruses [3-5]. Structurally, losudesivir is a cyclohexane carboxylate prodrug of the parent compound and active metabolite of remdesivir, GS-441524. Mechanistically RdRp inhibitors disrupt viral nucleic acid synthesis and thereby replication.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 153.76
Molecular weight 401.42
XLogP -0.32
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1CCC(CC1)C(=O)OC[C@@H]2[C@H]([C@H]([C@](C#N)(C3=CC=C4C(=NC=NN43)N)O2)O)O
Isomeric SMILES C1CCC(CC1)C(=O)OC[C@@H]2[C@H]([C@H]([C@](O2)(C#N)C3=CC=C4N3N=CN=C4N)O)O
InChI InChI=1S/C19H23N5O5/c20-9-19(14-7-6-12-17(21)22-10-23-24(12)14)16(26)15(25)13(29-19)8-28-18(27)11-4-2-1-3-5-11/h6-7,10-11,13,15-16,25-26H,1-5,8H2,(H2,21,22,23)/t13-,15-,16-,19+/m1/s1
InChI Key NJZZWWHRMAGFGB-ZIGSKRJUSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Bai J, Asakawa T, Yuan W, Lin Y, Ju H, Xu D, Yang M, Li S, Li G, Guo D et al.. (2025)
Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.
Virol J, 22 (1): 16. [PMID:39863888]
2. Sun C, Liu H, Ouyang Z, Ding J, Zhang Q, Ma H, Xu D, Zhang Q, Zhou R, Yang M et al.. (2024)
Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects.
Expert Opin Investig Drugs, 33 (5): 533-542. [PMID:38662639]
3. Yang S, Li K, Zhou Q, Zhang X, Guo D. (2025)
Broad-Spectrum Antiviral Activity of the Orally Bioavailable Antiviral ATV014 Against Multiple Coronaviruses.
MedComm (2020), 6 (5): e70186. [PMID:40242157]
4. Zheng P, Li G, Chen Y, Li S, Yang S, Guo D, Zhou Q, Zhang X. (2025)
Mini review: SHEN26, a novel oral antiviral drug for COVID-19 treatment.
Bioorg Med Chem Lett, 124: 130243. [PMID:40250816]
5. Zhou Q, Yang S, Cao L, Yang Y, Xu T, Chen Q, Lu H, Li Y, Guo D, Zhang X. (2023)
Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1'-CN-4-aza-7,9-dideazaadenosine C-nucleoside.
Signal Transduct Target Ther, 8 (1): 27. [PMID:36635259]